Literature DB >> 18642356

Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy.

Thomas Harbo1, Henning Andersen, Johannes Jakobsen.   

Abstract

In chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) the pathophysiology underlying permanent muscle weakness and sensory loss was studied in 22 stabilized long-term CIDP patients clinically characterized using isokinetic dynamometry, quantitative sensory testing, and neuropathy scores. Conduction velocity (CV), distal latency (DLAT), minimal F-wave latency (FLAT), compound muscle action potential (CMAP), and amplitude decay between distal and proximal stimulation sites were determined in the median, ulnar, peroneal, and tibial motor nerves and sensory CV and nerve action potentials in the median and sural nerves. Amplitude of CMAP and the DLAT were related to quantitative muscle strength, whereas CV, FLAT, amplitude decay, and dispersion were not consistently related to strength. Furthermore, CMAP and muscle strength were significantly more reduced distally than proximally. In conclusion, the electrophysiological signs of axonal loss and the associated length-dependent muscle weakness suggest secondary axonal loss in addition to primary demyelination in CIDP.

Entities:  

Mesh:

Year:  2008        PMID: 18642356     DOI: 10.1002/mus.21000

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

1.  Sensory and motor peripheral nerve function and longitudinal changes in quadriceps strength.

Authors:  Rachel E Ward; Robert M Boudreau; Paolo Caserotti; Tamara B Harris; Sasa Zivkovic; Bret H Goodpaster; Suzanne Satterfield; Stephen Kritchevsky; Ann V Schwartz; Aaron I Vinik; Jane A Cauley; Anne B Newman; Elsa S Strotmeyer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-10-15       Impact factor: 6.053

2.  Distal Acquired Demyelinating Symmetric Neuropathy Associated with Decreased Electrical Excitability of the Femoral Nerves.

Authors:  Vasily I Khodulev; Vladimir V Ponomarev; Julia I Stepanova
Journal:  Maedica (Bucur)       Date:  2021-12

3.  Fibular motor nerve conduction studies and ankle sensorimotor capacities.

Authors:  James K Richardson; Lara Allet; Hogene Kim; James A Ashton-Miller
Journal:  Muscle Nerve       Date:  2012-12-06       Impact factor: 3.217

Review 4.  Clinical applications of intravenous immunoglobulins in neurology.

Authors:  R A C Hughes; M C Dalakas; D R Cornblath; N Latov; M E Weksler; N Relkin
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

Review 5.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

Review 6.  The utility of electrodiagnostic tests for the assessment of medically unexplained weakness and sensory deficit.

Authors:  Josep Valls-Solé
Journal:  Clin Neurophysiol Pract       Date:  2016-04-02

7.  Length-dependent changes of lower limb muscle morphology in Chronic Inflammatory Demyelinating Polyneuropathy assessed with magnetic resonance imaging.

Authors:  Jacob Fanous; Alexander M Zero; Kevin J Gilmore; Timothy J Doherty; Charles L Rice
Journal:  Eur J Transl Myol       Date:  2021-11-18

8.  Loss of Schwann cell plasticity in chronic inflammatory demyelinating polyneuropathy (CIDP).

Authors:  Abhijeet R Joshi; Laura Holtmann; Ilja Bobylev; Christian Schneider; Christian Ritter; Joachim Weis; Helmar C Lehmann
Journal:  J Neuroinflammation       Date:  2016-09-27       Impact factor: 8.322

9.  Quantitative muscle ultrasound is useful for evaluating secondary axonal degeneration in chronic inflammatory demyelinating polyneuropathy.

Authors:  Keiichi Hokkoku; Kiyoshi Matsukura; Yudai Uchida; Midori Kuwabara; Yuichi Furukawa; Hiroshi Tsukamoto; Yuki Hatanaka; Masahiro Sonoo
Journal:  Brain Behav       Date:  2017-09-15       Impact factor: 2.708

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.